Ribonucleic Acid News and Research

RSS

Lab engineered human A549 lung cell model conducive for investigating SARS-CoV-2 antivirals

Researchers developed a human A549 lung epithelial cell-based model to probe SARS-CoV-2 replication.

9 Jan 2022

Multisystem inflammatory syndrome in children rare after COVID-19 vaccination in adolescents

The current study was based on merged results using the CDD’s surveillance database coupled with the Vaccine Adverse Event Reporting System (VAERS), along with reports from health departments or physicians to the CDC.

7 Jan 2022

Model suggests feasibility of shorter COVID-19 isolation period with minimal risk

Researchers set up a model that included parameters such as the infectiousness of the individual, and lateral flow testing, in order to assess the effectiveness of test-to-release policies as compared to those with fixed-duration isolation mandates

7 Jan 2022

Evaluating the response of lung cancer patients to COVID-19 mRNA vaccination

Researchers examine the efficacy of mRNA COVID-19 vaccination in NSCLC patients.

6 Jan 2022

How effective are COVID-19 vaccines against the Omicron and Delta variants?

Researchers study the effectiveness of COVID-19 vaccines against the SARS-CoV-2 Omicron and Delta variants.

6 Jan 2022

COVID-19 vaccines effective at varying intensities of SARS-CoV-2 exposure

Researchers investigate the effectiveness of COVID-19 vaccines in individuals at high risk due to their proximity with infected individuals.

6 Jan 2022

Small molecule identified as a SARS-CoV-2 inhibitor

A new study published in iScience reports the results of a screening strategy to identify small molecules that target viral entry to block infection with this virus.

6 Jan 2022

Host kinase identified as an inhibition target for SARS-CoV-2

In this experiment, the chemical probe SGC-CK2-1 inhibited virus replication at nanomolar concentration, showing a highly selective effect on the kinase.

6 Jan 2022

COVID boosters hinder SARS-CoV-2 Omicron

A new preprint research paper reports on the state of current knowledge as to the immune evasion capability of this variant, linking it to the type of vaccine used and the vaccination protocol.

6 Jan 2022

SARS-CoV-2 appears to persist in organs throughout the body for months

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leads to asymptomatic or mild symptoms in most cases. However, in a significant minority, it causes moderate or severe disease, with lung damage and sometimes multi-organ dysfunction, the origin of which is currently a matter of intense debate.

6 Jan 2022

A new model for predicting COVID-19 severity at diagnosis

Researchers estimate the probabilities of hospitalization and mortality from COVID-19 according to individual risk factors and number of vaccine doses.

5 Jan 2022

Monoclonal antibody treatment of COVID-19 reduces viral shedding

Researchers aim to understand the potential benefits of mAbs in preventing and treating SARS-CoV-2 infection.

5 Jan 2022

Exploring vaccine-induced cellular immunity against SARS-CoV-2 Omicron variant

In a new study, researchers determined CD8+ and CD4+ T cell responses against the SARS-CoV-2 Omicron variant in 51 individuals vaccinated with the messenger ribonucleic acid (mRNA)-based Pfizer and adenovirus vector-based Johnson & Johnson vaccines.

5 Jan 2022

COVID-19 mRNA vaccines offer protection against Omicron variant in pregnancy

A new study provides insights into the persistence of extra-neutralizing properties of mRNA vaccine-induced antibodies resulting in protection against the Omicron variant of SARS-CoV-2.

5 Jan 2022

mRNA booster vaccine confers strong protection against SARS-CoV-2 Omicron in cancer patients

A new preprint research paper posted to the medRxiv* server reports the induction of high neutralizing activity in these patients against the Omicron VOC with a booster dose.

5 Jan 2022

Transplant recipients benefit from a COVID-19 vaccine booster

A new preprint research paper posted to the medRxiv* server describes the reduction in humoral immunity in SOTR following vaccination, as well as the improvement with an additional dose of the vaccine.

4 Jan 2022